北極星藥業-KY (6550) 公告115年度股東常會重要決議事項
NQ 評分
44/100
AI 摘要（NQ 加工版）
Polaris Pharmaceuticals-KY (6550) held its 2026 Annual General Meeting on May 15, 2026. Key resolutions included approving the 2025 loss compensation, approving the 2025 business report and financial statements, and electing new directors (including independent directors). The meeting also approved lifting the non-compete restrictions for new directors, a capital reduction to offset losses, amendments to asset disposal procedures, and amendments to the Rules of Procedure for Shareholder Meetings. No amendments were made to the company's articles of incorporation.
尚無 AI 分析資料。
常見問題
- Q: 股東常會於何時召開？
- A: 股東常會於115年5月15日召開。
- Q: 本次股東常會通過了哪些重要決議？
- A: 本次股東常會通過了承認2025年度虧損撥補案、承認2025年度營業報告書及財務報表案、進行董事全面改選、解除新任董事競業禁止限制、辦理減資彌補虧損、修正取得或處分資產處理程序及股東會議事規則。
- Q: 公司章程是否有進行修訂？
- A: 無，公司章程並未進行修訂。
- Q: 該公司的股票代號為何？
- A: 該公司的股票代號為6550。